

Why sponsors are turning to decentralized clinical trials

80%

Of clinical trials do not meet enrollment deadlines

70%

Average patient retention rate across clinical trials

\$44.2B

Global clinical trials market size in 2018

95%

Retention rates maintained through use of “direct-to-patient” model

50%

Of patients are more likely to participate in a clinical trial if home care is offered

As sponsors seek innovative ways to increase enrollment, enhance compliance and lower drug development costs, there is growing interest in utilizing the decentralized model for clinical trials.

For 20+ years, Coram* Clinical Trials has led the adoption of patient-focused trials with our unsurpassed home care services and local and central pharmacy options.

70% average patient: <https://forteresearch.com/news/infographic/infographic-retention-in-clinical-trials-keeping-patients-on-protocols/>, accessed September 26, 2019.

\$44.2B global clinical trials market: <https://www.grandviewresearch.com/industry-analysis/global-clinical-trials-market>, accessed September 26, 2019.

95% retention rates: <http://www.appliedclinicaltrials.com/direct-patient-clinical-trials-strategies-success>, accessed September 26, 2019.

50% of patients: <http://www.appliedclinicaltrials.com/direct-patient-clinical-trials-strategies-success>, accessed September 26, 2019.

80% of clinical trials: <https://www.cognizant.com/whitepapers/patients-recruitment-forecast-in-clinical-trials-codex1382.pdf>, accessed September 26, 2019.

*Coram CVS Specialty Infusion Services.